🇺🇸 FDA
Patent

US 11834509

Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same

granted A61PA61P35/00A61P35/02

Quick answer

US patent 11834509 (Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P35/00, A61P35/02